Skip to main content

Table 1 Demographics and clinical features of overall cohort for patients with vs. without cancer a

From: Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma

Characteristics   Cancer subgroups
No cancer (n = 2,023) Total (N = 154) Breast (n = 65) Lung (n = 16) Haemato (n = 19) GI (n = 17) GU (n = 6) Gynae (n = 17) Skin (n = 6)
Sex
Female, n (%) 1,663 (82.2) 131 (85.1) 65 (100) 12 (75) 14 (73.7) 13 (76.5) 2 (33.3) 17 (100) 3 (50)
Male, n (%) 360 (17.8) 23 (14.9) NA 4 (25) 5 (26.3) 4 (23.5) 4 (66.7) NA 3 (50)
SSc/cancer onset
Median age (±SD) at SSc onset, years 45 (±14.1) 53 (±11.9) 53 (±11.1) 47 (±19.5) 51.5 (±9.4) 53 (±11.4) 59 (±18.4) 53 (±23.7) 59.5 (±19.1)
IQR = 35 to 55 IQR = 43 to 58 IQR = 44 to 58 IQR = 41 to 54 IQR = 44 to 56 IQR = 45 to 60 IQR39 to 68 IQR = 35 to 57 IQR = 46 to 63
Cancer prior to SSc onset (median ± SD), months No cancer 39.5 (±81.6) 36 (±77.3) NA 109 (±88.2) 8.5 (±27.7) 25 (±74.4) 141 (±104.8) NA
IQR = 12 to 125 IQR = 11 to 114 IQR = 29 to 190 IQR = 1 to 48 IQR = 4 IQR = 25 to 243
Cancer after SSc onset, (median ± SD), months No cancer 119 (±95.3) 108 (±108.5) 125 (±93.8) 101 (±73.4) 168 (±90.6) 116.5 (±79.9) 137 (±91.9) 62 (±55.5)
IQR = 41 to 185 IQR = 25 to 209 IQR = 71 to 200 IQR = 20 to 161 IQR = 119 to 233 IQR = 60 IQR = 20 to 194 IQR = 23 to 125
SSc subsets
dcSSc, n (%) 657 (32.5) 53 (34.4) 22 (33.8) 5 (31.3) 8 (42.1) 4 (23.5) 2 (33.3) 4 (23.5) 3 (50)
lcSSc, n (%) 1,260 (62.3) 98 (63.6) 42 (64.6) 11 (68.8) 11 (57.9) 12 (70.6) 3 (50) 13 (76.5) 3 (50)
Missing cases, n (%) 106 (5.2) 3 (1.9) 1 (1.5) 0 (0) 0 (0) 1 (5.9) 1 (16.7) 0 (0) 0 (0)
SSc autoantibody status
ACA, n (%) 550 (27.2) 40 (26) 17 (26.2) 2 (12.5) 4 (21.1) 8 (47.1) 1 (16.7) 6 (35.3) 1 (16.7)
Scl to 70, n (%) 416 (20.6) 28 (18.2) 10 (15.4) 5 (31.3) 5 (26.3) 1 (5.9) 1 (16.7) 4 (23.5) 1 (16.7)
RNAP, n (%) 247 (12.2) 41 (26.6) 19 (29.2) 4 (25) 5 (26.3) 3 (17.6) 2 (33.3) 3 (17.6) 3 (50)
Others, n (%) 515 (25.4) 31 (20) 13 (19.9) 3 (18.9) 4 (21) 3 (17.6) 1 (16.7) 4 (23.6) 1 (16.7)
ANA-negative, n (%) 75 (3.7) 9 (5.8) 4 (6.2) 0 (0) 1 (5.3) 2 (11.8) 1 (16.7) 0 (0) 0 (0)
Missing cases, n (%) 220 (10.9) 5 (3.2) 2 (3.1) 2 (12.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Organ involvementb
Lung fibrosis, n (%) NA 52 (33.8) 24 (36.9) 8 (50) 6 (31.6) 4 (23.5) 3 (33.3) 2 (11.8) 2 (33.3)
PAH, n (%) NA 27 (17.5) 15 (23.1) 1 (6.3) 3 (15.8) 3 (17.6) 0 (0) 2 (11.8) 1 (16.7)
GI, n (%) NA 85 (55.2) 35 (53.8) 9 (56.3) 12 (63.2) 9 (52.9) 1 (16.7) 10 (58.8) 3 (50)
SRC, n (%) NA 16 (10.4) 4 (6.2) 1 (6.3) 2 (10.5) 4 (23.5) 1 (16.7) 2 (11.8) 0 (0)
  1. aACA, Anticentromere antibody; ANA, Antinuclear antibody; dcSSc, Diffuse cutaneous systemic sclerosis; GI, Gastrointestinal; GU, Genitourinary; Gynae, Gynaecological; Haemato, Haematological; IQR, Interquartile range; lcSSc, Limited cutaneous systemic sclerosis; NA, Not applicable; PAH, Pulmonary arterial hypertension; RNAP, RNA polymerase III; SRC, Scleroderma renal crisis; SSc, Systemic sclerosis. Cohort sample populations comprised 154 SSc patients with cancer and 2,023 SSc patients without cancer. bExtent and pattern of organ involvement is defined in the Methods section.